Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794229 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
A Phase 2 study of Locally Advanced Renal Cell Carcinoma, sponsored by Qian Qin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT06794229 is a Phase 2 study of Locally Advanced Renal Cell Carcinoma that is actively recruiting participants, run by Qian Qin. The registered enrollment target is 69 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06794229, a Phase 2 study of Locally Advanced Renal Cell Carcinoma, is actively recruiting participants, sponsored by Qian Qin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed by restaging scan/evaluation for surgical operability and an adaptive approach that includes (1) surgical resection if the participant is eligible for surgery (Cohort A), (2) up to 48 weeks total (from Cycle 1 Day 1) of zanzalintinib plus nivolumab if the participant has partial response or stable disease but remains inoperable (Cohort B1), or (3) stopping protocol mandated treatment to receive standard of care systemic therapy and continue follow up per protocol if the participant has disease progression (Cohort B2).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Zanzalintinib
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06794229
The ClinicalTrials.gov registry entry for NCT06794229 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qian Qin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT06794229 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06794229 about?
NCT06794229 is a clinical study titled "Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis". All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed by restaging scan/evaluation for surgical operability and an adaptive approach that includes (1) surg...
What is the current status of trial NCT06794229?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2025-10-30. Estimated completion is 2029-06.
What conditions does trial NCT06794229 study?
This clinical trial studies the following conditions: Locally Advanced Renal Cell Carcinoma.
What interventions are being tested in trial NCT06794229?
The interventions under investigation include: Nivolumab (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06794229?
This trial is sponsored by Qian Qin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794229 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.